FLC News

New Direct-to-SBIR Phase II Funding Award for NIAID Intramural Diagnostic Inventions

nih imagebank 1515 150

The National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH), is pleased to announce the first NIAID Small Business Innovation Research-Technology Transfer (SBIR-TT) Direct-to-Phase II awards to move commercially viable diagnostic technologies from NIAID intramural research laboratories into the marketplace.

Direct-to-Phase II awards of up to $2M allow small businesses to compete even if they did not receive a Phase I SBIR award for research in the same area. An SBIR Phase II research and development plan tests the viability of the technology scientifically, as well as its potential for commercialization. This Funding Opportunity Announcement (FOA) offers 18 diagnostic inventions for further development by small businesses. The list includes technologies related to hepatitis, cancer, and tropical diseases, as well as other areas. As the lead federal organization conducting and supporting scientific research on infectious and immunologic diseases, NIAID carries out basic, applied, and clinical investigations within intramural laboratories, and provides extramural grant, cooperative agreement, and contract support to research scientists worldwide. Any project that fits within the NIAID mission and relies on the use of NIAID’s listed intramural technologies is eligible for this award.

Please contact Dr. Haiqing Li to discuss NIAID inventions. See FOA: NIAID SBIR - Technology Transfer Direct Phase II (SBIR-TT) (R44) for the details on eligibility and applying, or see the FAQ page for additional information.

Category: 
FLC News